COMPANY

Oxalo Therapeutics, Inc.

Keywords: From press sources:renal nephrolithiasis

Profile checked Oct 10, 2026

NIH awards 3

Annual award amounts. Total $2.3M.

Aug 13, 2020 NIH award 5R42DK120261-03 FY2020: $999,995 awarded for that fiscal year; activity R42 (STTR); PI ARVANS, DONNA; recipient as written: OXALO THERAPEUTICS, INC., CHICAGO, IL. Developing a peptide-based oral drug to pre source ↗
Aug 23, 2019 NIH award 4R42DK120261-02 FY2019: $999,998 awarded for that fiscal year; activity R42 (STTR); PI ARVANS, DONNA; recipient as written: OXALO THERAPEUTICS, INC., CHICAGO, IL. Developing a peptide-based oral drug to pre source ↗
Sep 19, 2018 NIH award 1R42DK120261-01 FY2018: $299,998 awarded for that fiscal year; activity R42 (STTR); PI ARVANS, DONNA; recipient as written: OXALO THERAPEUTICS, INC., CHICAGO, IL. Developing a peptide-based oral drug to pre source ↗